Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Drug Profile

Bemcentinib - BerGenBio/Rigel Pharmaceuticals

Alternative Names: BGB 324; R-428

Latest Information Update: 10 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; University of Leicester; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Antivirals; Benzocycloheptenes; Cycloheptanes; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer; COVID 2019 infections; Malignant melanoma; Mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer
  • Phase I/II Glioblastoma; Pancreatic cancer
  • Preclinical Ebola virus infections; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Zika virus infection
  • No development reported Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 08 Mar 2021 Pharmacodynamics data from a preclinical studies in COVID-2019 infections released by BerGenBio
  • 10 Feb 2021 Efficacy data from the phase II BERGAMO trial in Myelodysplastic syndrome released by BerGenBio
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Second-line therapy or greater) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top